The 505(b)(2) Platform 2021 Annual Meeting

---

---

---

tsmith_non-con_deck_anmeet_2021.pdf
File Size:	371 kb
File Type:	pdf

Download File

---

---

---

Opening Remarks - Ed Allera

---

Regulatory Considerations for 505(b)(2) NDAs - James Myers FDA

---

505(b)(2) Products: An Investor's Perspective - David Crean, Ph.D.

---

​Deals & Diligence - Todd Smith
For confidentiality reasons we are not able to share Todd Smiths presentation. Rather, Todd has graciously supplied a non-confidential deck for your review.

---

505(b)(2)'s from a Sponsor View - Aziza Johnson

---

Strategic Considerations for 505(b)(2) Drug Application - Kush Dhody, Ph.D.